Abstract
Purpose :
We performed a 24-month follow-up prospective single-arm clinical study to evaluate the safety and efficacy of SRT using a Q-switched neodymium-doped yttrium lithium fluoride (Nd:YLF) laser with Real-Time Feedback (RTF) technology in a group of CSC patients
Methods :
Fifty patients (53 eyes) with CSC were treated with an SRT laser system equipped with RTF technology(R:GEN®, Lutronic, South Korea). At baseline, 1, 3, and 6 months after treatment visits, best-corrected visual acuity (BCVA), central retinal thickness (CRT), and subretinal fluid (SRF) height were measured and evaluated. Treatment outcomes for 24-month follow-up were also evaluated for available patients
Results :
During the 6-month follow-up, complete SRF resolution was achieved in 32 of 52 eyes (61.5%), CRT (mean ± SD) was reduced from 350.6 ± 100.1 µm at baseline to 268.2 ± 70.6µm (p<0.001), peak SRF height (mean ± SD) was reduced from 152.1 ± 86.1 µm at baseline to 63.4 ± 76.3µm (p < 0.001), and mean BCVA (LogMAR, mean ± SD) was improved from 0.15 ± 0.18 at baseline to 0.12 ± 0.21 without statistical significance (p = 0.062). A significant correlation between the peak SRF height reduction and BCVA change at 6 months was found with the Pearson coefficient of -0.36 (p = 0.009). No correlation between any treatment outcomes and symptom duration was found. Long-term follow-up data showed continuous significant improvement in both BCVA and CRT until 24 months after treatment. No treatment-related adverse events were not observed
Conclusions :
SRT with RTF technology at the parameters used in the current clinical trial was a well-tolerated and effective treatment for CSC regardless of symptom duration. BCVA and CRT improvement can be kept up to 24 months after treatment.
This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.